Clazakizumab Completed Phase 2 Trials for Rheumatoid Arthritis Treatment

Indications	Status	Purpose	Phase
DBCOND0027961 (Rheumatoid Arthritis)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02015520	Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis	Clazakizumab (DB12849)
NCT01373151	Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate	Adalimumab (DB00051) Clazakizumab (DB12849) Methotrexate (DB00563)